Your Omega Ratios Are Imbalanced. Your Genes May Control Why.

The FADS1 gene encodes the delta-5 desaturase enzyme, which catalyzes the final step in converting dietary omega-3 precursors (ALA) into EPA, the active long-chain form your tissues need. This enzyme sits at a critical checkpoint. Without it working efficiently, your body stalls in the conversion pipeline and you end up with low EPA even if you’re consuming adequate ALA from flax, chia, or walnuts.

The rs174537 variant in FADS1, carried by roughly 30 to 40 percent of people, reduces delta-5 desaturase activity. People with this variant convert ALA to EPA at 30 to 40 percent lower efficiency than wild-type carriers. That’s not a small effect. It’s a fundamental metabolic bottleneck that standard dietary advice completely misses.

What this means for you: if you have the FADS1 variant, eating more plant-based omega-3 sources will not meaningfully raise your EPA or DHA. Your cells are working at partial capacity. You experience this as persistent inflammation despite a “good” diet, joint stiffness that doesn’t resolve with fish oil, and cardiovascular risk markers that don’t budge when you cut seed oils. Your body is literally unable to manufacture EPA fast enough to meet its needs.

The FADS2 gene encodes delta-6 desaturase, the enzyme that catalyzes the very first committed step in the omega-3 conversion pathway. ALA arrives, and delta-6 desaturase must transform it into a longer intermediate before the rest of the cascade can proceed. This is the rate-limiting step. If this enzyme is slow, everything downstream stalls, no matter how much ALA you consume.

The rs1535 variant in FADS2, present in roughly 30 to 40 percent of the population, reduces delta-6 desaturase activity by 30 to 40 percent. This single variant can reduce your entire EPA and DHA synthesis pipeline by half because it affects the entry point into the pathway. You can eat a perfect omega-3 diet and your body simply cannot process it into usable form.

What this means for you: if you have this variant, your omega-3 deficiency is not a dietary failure. It’s an enzymatic ceiling. You may also notice that you handle omega-6 differently than others; because the same FADS2 enzyme regulates omega-6 conversion as well, the variant typically causes a relative omega-6 accumulation as your body compensates by shifting toward omega-6 synthesis. This drives inflammation and worsens your ratio without any conscious dietary shift.

The PPARG gene encodes a nuclear receptor that acts like a metabolic master switch for fat storage and utilization. When PPARG is activated (often by omega-3s themselves), it reduces inflammation, improves insulin sensitivity, and shifts your body toward metabolizing fat efficiently rather than storing it. It’s one of the reasons omega-3 supplementation helps some people so dramatically: the EPA and DHA directly activate PPARG and reset your whole metabolic posture.

But if you carry certain PPARG variants, your receptor is less responsive to omega-3 signals. This means even adequate EPA and DHA may not trigger the anti-inflammatory and metabolic benefits that wild-type carriers experience automatically. Your cells hear the omega-3 signal but don’t respond as strongly. You’re getting the omega-3s in, but your body isn’t translating them into the downstream benefits.

What this means for you: higher omega-3 intake alone may not resolve your inflammation or metabolic dysfunction. You may need higher doses, longer treatment periods, or concurrent interventions (like increased physical activity or targeted polyphenol intake) to activate PPARG signaling strongly enough to see results. You also may accumulate more abdominal fat or have stubborn insulin resistance despite reasonable dietary choices.

The APOE gene encodes the protein that packages lipids (including omega-3 and omega-6 fatty acids) into lipoproteins for transport through your bloodstream and uptake into tissues. You inherit two copies of APOE, and each copy is one of three variants: E2, E3, or E4. Your APOE genotype fundamentally determines how your body handles all dietary fats, including your precious omega-3s.

APOE3 is the ancestral and most flexible form. APOE2 carriers tend to accumulate triglycerides more readily and may have lower LDL but less efficient omega-3 transport into brain tissue. APOE4 carriers, roughly 25 to 30 percent of European ancestry populations, handle dietary fat differently: they absorb and recycle cholesterol more efficiently, but they are also more sensitive to the ratio of omega-6 to omega-3 in their diet. If your ratio is imbalanced, APOE4 carriers experience more vascular and neuroinflammatory effects than other genotypes.

What this means for you: if you’re an APOE4 carrier, your omega balance is not just a preference. It’s a biological necessity. An imbalanced ratio (high omega-6, low omega-3) drives accelerated vascular aging and neuroinflammation in your genotype specifically. Other genotypes can tolerate slightly suboptimal ratios; APOE4 cannot. You also may need higher absolute amounts of omega-3 to see benefits because your lipid transport system handles them differently.

The MTHFR gene encodes the enzyme that converts folate into its active form, 5-methyltetrahydrofolate, which is essential for the methylation cycle. Methylation is not just about processing B vitamins. It’s a fundamental biochemical process that regulates inflammation, modulates gene expression, and controls how efficiently your body metabolizes all nutrients including fatty acids. Your methylation capacity directly influences how well your body can process omega-3s and manage omega-6 inflammation.

The C677T and A1298C variants in MTHFR, carried by roughly 40 percent of people of European ancestry, reduce enzyme efficiency by 30 to 40 percent. This impairs the entire methylation cycle, which cascades into reduced capacity to synthesize and utilize EPA and DHA, and increased vulnerability to omega-6-driven inflammation. Your body has fewer methyl groups available to regulate the inflammatory pathways that omega-6 activates.

What this means for you: if you have an MTHFR variant, your omega balance problem may not resolve with omega-3 supplementation alone. You’re also running a methylation deficit. You may experience fatigue despite omega-3 supplementation, continued brain fog, or persistent inflammatory markers because your body cannot methylate efficiently enough to process the omega-3s you’re taking or to suppress the inflammatory signals from omega-6 adequately.

The VDR gene encodes the vitamin D receptor, a nuclear receptor that sits inside your cells and responds to activated vitamin D (1,25-dihydroxyvitamin D3). When vitamin D binds to VDR, it regulates hundreds of genes, including many involved in immune regulation, inflammation control, and metabolism. Omega-3s and vitamin D work synergistically: EPA and DHA activate anti-inflammatory pathways, and vitamin D amplifies those effects by increasing VDR sensitivity and expression.

If you carry certain VDR variants (BsmI, FokI, TaqI polymorphisms), your cells are less responsive to vitamin D signaling. Roughly 30 to 50 percent of people carry a functionally significant variant. This means even if your 25-hydroxyvitamin D blood level is technically “normal,” your cells are not receiving the vitamin D signal strongly enough to suppress omega-6-driven inflammation or activate the gene expression changes that omega-3s depend on to work. You’re vitamin D insensitive at the cellular level, even if your serum 25(OH)D looks fine on paper.

What this means for you: if you have a VDR variant, omega-3 supplementation alone will be blunted because vitamin D and omega-3 work in concert to regulate inflammation. You may need higher vitamin D intake to achieve the same cellular effect as wild-type carriers, and the omega-3 benefits will remain constrained until vitamin D signaling is restored. You may also have worse joint pain, more seasonal mood changes, or slower exercise recovery because both omega-3 and vitamin D effects are compromised.